Physician profile
Robert M Applebaum
NPI 1932193323
$9,842.29
in general payments reported to CMS, 2019-2025
30 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,239 · 2020: $1,872 · 2021: $3,144 · 2022: $1,623 · 2023: $667 · 2024: $193 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $964.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,648.98 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,582.23 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,543.97 | 2019-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $817.46 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $711.04 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $703.05 | 2019-2023 | Farxiga |
| Amarin Pharma, INC. | $530.56 | 2019-2022 | |
| Pfizer INC. | $411.71 | 2019-2023 | |
| Esperion Therapeutics, INC. | $352.60 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $323.44 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $148.13 | 2019-2022 | |
| Gilead Sciences, INC. | $144.68 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $136.64 | 2019-2022 | |
| Boston Scientific Corporation | $109.00 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $99.92 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $85.16 | 2019-2021 | |
| Novo Nordisk INC | $70.77 | 2021-2022 | |
| Vifor Pharma, INC. | $53.67 | 2021 | |
| Lilly USA, LLC | $49.60 | 2019-2020 | |
| Biobeat USA INC. | $43.39 | 2024 | Bb-613 Bpm Kit |
| Regeneron Healthcare Solutions, INC. | $41.35 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $40.91 | 2024 | |
| Irhythm Technologies, INC. | $37.70 | 2023 | Zio Xt Patch |
| Actelion Pharmaceuticals US, INC. | $30.58 | 2022 | |
| Heartflow, INC. | $25.17 | 2025 | |
| Allergan, INC. | $23.83 | 2021 | |
| Althera Pharmaceuticals LLC | $22.31 | 2021 | |
| Tepha INC | $21.22 | 2020 | |
| Philips North America LLC | $20.65 | 2022 | |
| Abbott Laboratories | $12.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Applebaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.